The company has world-class expertise in medicinal chemistry and an experienced management team led by CEO Peter Worrall and Research Director Dr Marc Hummersone. Between them the Pharminox team have proven track records in the discovery and development of several leading marketed anti-cancer agents, including the blockbuster drugs temozolomide (Temodar, Merck & Co, Inc) and erlotinib (Tarceva, Roche-Genentech and OSI Pharmaceuticals).
Pharminox was formed in 2002 as a spin-out from Oxford University. Our operations are now based at the BioCity facility in Nottingham, UK.
Through in-house discovery and targeted in-licensing, we are building a portfolio of small molecule drug candidates that have the potential to be first in class with multiple applicability across some of the most common types of cancer.